Gill Capital Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Gill Capital Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14	Hold	4	–	–	﹤0.01%	696
2026 Q1	$14	Buy	+4	New	+$16	﹤0.01%	695

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Gill Capital Partners's RCKT Position: Q2 2026 in Review

Gill Capital Partners held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 4 shares worth $14. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Gill Capital Partners first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Gill Capital Partners held 4 shares of Rocket Pharmaceuticals worth $14 as of Q2 2026.
Gill Capital Partners left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
Rocket Pharmaceuticals made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #696 holding.
Gill Capital Partners first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.